52North raises £3.2m led by Macmillan Ventures

Cambridge-based 52North has raised £3.2m in a seed round, led by Macmillan Ventures. It builds a finger-prick blood test that flags chemotherapy patients at risk of neutropenic sepsis. Hargreave Hale AIM VCT, Cedars Sinai Intellectual Property Company, Cancer Research Horizons and others also invested. The money will go on clinical validation, regulatory milestones and UK launch preparation.